B. Grabowski

发表

The Effect of Hepatic Insufficiency on the Safety and Pharmacokinetics of Paricalcitol (Zemplar®)

M. Chojkier, L. Williams, C. Locke, 2006, Nephron Clinical Practice.

Absorption, Distribution, Metabolism and Excretion of [14C]Dexlansoprazole in Healthy Male Subjects

R. Lee, B. Grabowski, 2012, Clinical Drug Investigation.

Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects

R. Khosravan, L. Vernillet, B. Grabowski, 2006, Clinical pharmacokinetics.

ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease

Dale J. Kempf, John M. Leonard, Jacob J. Plattner, 1998, Antimicrobial Agents and Chemotherapy.

Hepatic drug-metabolizing activities in rats after 14 days of oral administration of the human immunodeficiency virus-type 1 protease inhibitor ritonavir (ABT-538).

J. Denissen, G. Kumar, B. Grabowski, 1996, Drug Metabolism And Disposition.

Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.

R. Khosravan, L. Vernillet, B. Grabowski, 2008, British journal of clinical pharmacology.

Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus.

J. Leonard, A. Molla, S. Vasavanonda, 1998, Virology.

Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.

R. Khosravan, L. Vernillet, C. Lademacher, 2010, British journal of clinical pharmacology.

The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase

R. Khosravan, L. Vernillet, M. D. Mayer, 2006, Journal of clinical pharmacology.

Metabolism and Excretion of [14C] Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase, in Healthy Male Subjects

R. Khosravan, D. Mulford, L. Vernillet, 2011, Journal of clinical pharmacology.

Metabolism and Disposition of the HIV-1 Protease Inhibitor Lopinavir (ABT-378) Given in Combination with Ritonavir in Rats, Dogs, and Humans

D. Kempf, H. Sham, K. Marsh, 2004, Pharmaceutical Research.

Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.

D. Kempf, J. Denissen, A. Buko, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Effect of food or antacid on febuxostat pharmacokinetics and pharmacodynamics in healthy subjects

L. Vernillet, J. Wu, B. Grabowski, 2005 .

In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification.

D. Kempf, H. Sham, D. Betebenner, 1999, Drug metabolism and disposition: the biological fate of chemicals.